
In a federally funded study that enrolled more than 500 patients from U.S. hospital emergency departments, administering COVID-19 convalescent plasma to high-risk COVID-19 outpatients with early symptoms did not prevent disease progression, according to final results reported in the New England Journal of Medicine.